Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated

BMC Medical Research Methodology

Volumn 16, Issue 1, 2016, Pages

  Royston, Patrick ^a   Parmar, Mahesh K B ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Design; Flexible parametric model; Hazard ratio; Logrank test; Non proportional hazards; Permutation test; Randomized controlled trials; Restricted mean survival time; Simulation; Time to event data

Indexed keywords

ALGORITHM; CLINICAL TRIAL (TOPIC); HUMAN; KAPLAN MEIER METHOD; METHODOLOGY; OUTCOME ASSESSMENT; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; SAMPLE SIZE; STANDARDS; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL; TIME FACTOR;

ALGORITHMS; CLINICAL TRIALS AS TOPIC; HUMANS; KAPLAN-MEIER ESTIMATE; MODELS, THEORETICAL; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SAMPLE SIZE; TIME FACTORS;

EID: 84957635492     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/s12874-016-0110-x     Document Type: Article

References (22)

1. Royston P, Parmar MKB. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect. Trials. 2014; 15:314. doi: http://dx.doi.org/10.1186/1745-6215-15-314.
2. Schemper M, Wakounig S, Heinze G. The estimation of average hazard ratios by weighted Cox regression. Stat Med. 2009; 28:2473-89.
3. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81:515-26.
4. Royston P, Parmar MKB. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011; 30:2409-21.
5. Irwin JO. The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice. J Hyg. 1949; 47:188-9.
6. Andersen PK, Hansen MG, Klein JP. Regression analysis of restricted mean survival time based on pseudo-observations. Lifetime Data Anal. 2005; 10:335-50.
7. Parner ET, Andersen PK. Regression analysis of censored data using pseudo-observations. Stata J. 2010; 10:408-22.
8. Overgaard M, Andersen PK, Parner ET. Regression analysis of censored data using pseudo-observations: an update. Stata J. 2015; 15:809-21.
9. Klein JP, Gerster M, Andersen PK, Tarima S, Perme MP. SAS and R functions to compute pseudo-values for censored data regression. Comput Methods Prog Biomed. 2008; 89:289-300.
10. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al.Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334:1-6.
11. Thomas KS. others for the PATCH1 Trial Team. Penicillin to prevent recurrent leg cellulitis. N Engl J Med. 2013; 368:1695-703.
12. Perren TJ. others for the ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365:2484-96.
13. Winnett A, Sasieni P. Iterated residuals and time-varying covariate effects in Cox regression. J R Stat Soc Series B. 2003; 65:473-88.
14. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al.Effect of coronary artery bypass graft on survival: overview of ten-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994; 344:563-70.
15. Andersen PK, Perme MP. Pseudo-observations in survival analysis. Stat Methods Med Res. 2010; 19:71-99.
16. Royston P. Tools to simulate realistic censored survival-time distributions. Stata J. 2012; 12:639-54.
17. Barthel FMS, Royston P, Babiker A. A menu-driven facility for complex sample size calculation in randomized controlled trials with a survival or a binary outcome: update. Stata J. 2005; 5:123-9.
18. Barthel FMS, Babiker A, Royston P, Parmar MKB. Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over. Stat Med. 2006; 25:2521-42.
19. Li H, Han D, Hou Y, Chen H, Chen Z. Statistical inference methods for two crossing survival curves: a comparison of methods. PLOS ONE. 2015; 10:e0116774. doi: http://dx.doi.org/10.1371/journal.pone.0116774.
20. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika. 1982; 69:553-66.
21. Tarone RE, Ware J. On distribution-free tests for equality of survival distributions. Biometrika. 1977; 64:156-60.
22. Uno H, Tian L, Claggett B, Wei LJ. A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves. Stat Med. 2015; 34. doi: http://dx.doi.org/10.1002/sim.6591.